{'fraction_non_alphanumeric': 0.0480225988700565, 'fraction_numerical': 0.022598870056497175, 'mean_word_length': 5.752380952380952, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma

The authors previously reported results from a randomized trial of standard‐dose chemotherapy with combined 5‐fluorouracil (1000 mg/m2 per cycle), doxorubicin (50 mg/m2 per cycle), and cyclophosphamide (500 mg/m2 per cycle) (FAC) versus FAC followed by high‐dose chemotherapy (HDCT) and autologous stem cell support (ASCS) for patients with high‐risk primary breast carcinoma. After a median follow‐up of 6.5 years, no significant differences were observed in recurrence‐free survival (RFS) or overall survival (OS) between the 2 arms. This report updates the survival analyses.